Dr Schlicher heads commercial work at Genialis, where she recently led strategy and launch for Genialis ResponderIDTM. She brings over 20 years of experience in precision medicine, diagnostics, and entrepreneurial leadership. Robyn has patented inventions in regenerative medicine and is a recognized global expert in advanced analytical techniques. Her publication on drug delivery by targeted cavitation has been widely cited and highlighted worldwide. She earned her doctorate in bioengineering from Georgia Institute of Technology and Emory University, receiving National Institutes of Health and Medtronic fellowships. In 2021, Robyn became an inaugural fellow of On Deck Health (ODH1).
Clinical Dx Showcase:
Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. Its clinical biomarker discovery platform, ResponderID™, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development.
Machine-Learning for Clinical Biomarker Discovery
The research space churns out biomarkers while the clinical space struggles to deliver them for patient reporting. I will discuss biomarker development challenges and describe ML-enabled and ML-enabling solutions Genialis uncovered on the road to validating a clinical assay.
The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.